Across TCGA pan-cancer cohorts, TRMT112P2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of TRMT112P2’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRMT112P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRMT112P2 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.
KIRC and THCA are the cancer types where TRMT112P2 tumor–normal differential expression is most reproducible.